Prognostic and Predictive Value of K-RAS Mutations in Non-Small Cell Lung Cancer

[1]  P. Hainaut,et al.  Lace-Bio Pooled Analysis of the Prognostic and Predictive Value of TP53 Mutations in Completely Resected Non Small Cell Lung Cancer (NSCLC) , 2012 .

[2]  K. O'Byrne,et al.  Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study. , 2011, The Lancet. Oncology.

[3]  R. Rosell,et al.  The identification of KRAS mutations at codon 12 in plasma DNA is not a prognostic factor in advanced non-small cell lung cancer patients. , 2011, Lung cancer.

[4]  R. Govindan,et al.  Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  T. Trikalinos,et al.  Systematic Review: Anti–Epidermal Growth Factor Receptor Treatment Effect Modification by KRAS Mutations in Advanced Colorectal Cancer , 2011, Annals of Internal Medicine.

[6]  T. Mao,et al.  Loss of Immunolabeling of kruppel like factor 10 is associated with advanced stage and rapid progression of pancreatic cancer , 2010 .

[7]  Jin Li,et al.  KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a meta-analysis of 22 studies. , 2010, Lung cancer.

[8]  D. Mavroudis,et al.  Clinical outcome of patients with non-small cell lung cancer receiving front-line chemotherapy according to EGFR and K-RAS mutation status. , 2010, Lung cancer.

[9]  G. Giaccone,et al.  Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. , 2010, The Lancet. Oncology.

[10]  D. Gandara,et al.  KRAS mutations (MTs) in non-small cell lung cancer (NSCLC) versus colorectal cancer (CRC): Implications for cetuximab therapy. , 2010 .

[11]  X. Wang,et al.  Relationship between NFKB1 -94 insertion/deletion ATTG polymorphism and susceptibility of cervical squamous cell carcinoma risk. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  C. Horak,et al.  Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Nicholas Iannotti,et al.  Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Edward S. Kim,et al.  Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  J. Ahn,et al.  Randomized Phase III Trial of Gefitinib versus Docetaxel in Non–Small Cell Lung Cancer Patients Who Have Previously Received Platinum-Based Chemotherapy , 2010, Clinical Cancer Research.

[16]  S. Toyooka,et al.  Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. , 2010, The Lancet. Oncology.

[17]  A. Jemal,et al.  Cancer Statistics, 2009 , 2009, CA: a cancer journal for clinicians.

[18]  J. Abbruzzese,et al.  F1000 highlights , 2009, JAMA.

[19]  V. Miller,et al.  A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Edward S. Kim,et al.  Comparison of gefitinib and docetaxel in patients with pretreated advanced non-small cell lung cancer (NSCLC): Meta-analysis from four clinical trials. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Robert Pirker,et al.  Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial , 2009, The Lancet.

[22]  Edward S. Kim,et al.  Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial , 2008, The Lancet.

[23]  F. Siannis,et al.  Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. , 2008, The Lancet. Oncology.

[24]  Lesley Seymour,et al.  Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  Kenji Eguchi,et al.  Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  M. Ladanyi,et al.  Frequency and Distinctive Spectrum of KRAS Mutations in Never Smokers with Lung Adenocarcinoma , 2008, Clinical Cancer Research.

[27]  A. Jemal,et al.  Cancer Statistics, 2008 , 2008, CA: a cancer journal for clinicians.

[28]  V. Seshan,et al.  Prognostic and Therapeutic Implications of EGFR and KRAS Mutations in Resected Lung Adenocarcinoma , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[29]  Roy S Herbst,et al.  KRAS Mutation Is an Important Predictor of Resistance to Therapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer , 2007, Clinical Cancer Research.

[30]  M. Meyerson,et al.  Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  G. Giaccone,et al.  Erlotinib for Frontline Treatment of Advanced Non–Small Cell Lung Cancer: a Phase II Study , 2006, Clinical Cancer Research.

[32]  T. Čufer,et al.  Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer , 2006, Anti-cancer drugs.

[33]  M. Stratton,et al.  COSMIC 2005 , 2006, British Journal of Cancer.

[34]  M. Ostland,et al.  Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  P. Jänne,et al.  Differential Effects of Gefitinib and Cetuximab on Non–small-cell Lung Cancers Bearing Epidermal Growth Factor Receptor Mutations , 2005 .

[36]  Edward S. Kim,et al.  Phase II study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in patients with taxane‐refractory/resistant nonsmall cell lung carcinoma , 2005, Cancer.

[37]  Renato Martins,et al.  Erlotinib in previously treated non-small-cell lung cancer. , 2005, The New England journal of medicine.

[38]  H. Varmus,et al.  Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain , 2005, PLoS medicine.

[39]  M Paesmans,et al.  The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis , 2004, British Journal of Cancer.

[40]  Li Mao,et al.  Prognostic factors in resected stage I non-small-cell lung cancer: a multivariate analysis of six molecular markers. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  R. Wilson,et al.  EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[42]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[43]  Daniel Jones.  Anticancer drugs: To the rescue? , 2004, Nature Reviews Drug Discovery.

[44]  R. Marks,et al.  Phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced non-small-cell lung cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  E. Mark,et al.  Implications and prognostic value of K-ras mutation for early-stage lung cancer in women. , 1999, Journal of the National Cancer Institute.

[46]  S. Rodenhuis,et al.  K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. , 1990, The New England journal of medicine.

[47]  Joyce Bos.  ras oncogenes in human cancer: a review. , 1989, Cancer research.

[48]  S. Rodenhuis,et al.  Mutational activation of the K-ras oncogene. A possible pathogenetic factor in adenocarcinoma of the lung. , 1987, The New England journal of medicine.

[49]  L. Tanoue.  Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR , 2011 .

[50]  L. Tanoue.  Cancer Statistics, 2009 , 2010 .

[51]  L. Tanoue,et al.  Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma , 2010 .

[52]  V. Miller,et al.  A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  N. Hanna,et al.  Vinorelbine Plus Cisplatin vs Observation in Resected Non–Small-Cell Lung Cancer , 2006 .

[54]  N. Hanna,et al.  EGF Receptor Gene Mutations Are Common in Lung Cancers From “Never Smokers” and Are Associated With Sensitivity of Tumors to Gefitinib and Erlotinib , 2006 .

[55]  P. Jänne,et al.  Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations. , 2005, Journal of the National Cancer Institute.